In the name of GOD In the name of GOD.

Slides:



Advertisements
Similar presentations
The efficacy of ‘Basal supported Oral Therapy ’ with ‘Sitagliptin’ in Japanese type 2 diabetes patients: Yoshihiko Suzuki HDC Atlas Clinic,
Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
4-T Final Three-year Results Slides © University of Oxford Diabetes Trials Unit  4-T slides are copyright and remain the property of the University of.
Farxiga™ - Dapagliflozin
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.
Insulin therapy.
P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.
A joint investigation by Channel 4 News and the BMJ reveals the NHS spends tens of millions more than necessary on modern insulins to treat diabetes despite.
INSULIN THERAPY IN TYPE 1 DIABETES
PRE-EXISTING DIABETES AND PREGNANCY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.
Quality of life improves after patients switch to biphasic insulin aspart 30/70 (BIAsp 30): IMPROVE™ Study data from 39,015 patients M. Benroumpi 1, T.
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
How to Analyze Systematic Reviews: practical session Akbar Soltani.MD. Tehran University of Medical Sciences (TUMS) Shariati Hospital
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
The Effects of Qigong Therapy on Glucose Management in Patients with Type 2 Diabetes Guan-Cheng Sun, Ph.D., Jennifer Lovejoy, Ph.D., Sara Gillham, N.D.
Toujeo® and it’s Place in Therapy
Patient-directed titration to achieve glycaemic goals in type 2 diabetes using once-daily basal insulin: results of the TITRATE randomized controlled trial.
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
Clinical Practice Glycemic Management of Type 2 Diabetes Mellitus Faramarz Ismail-Beigi, M.D., Ph.D. Dr.kalantar N Engl J Med Volume 366(14):
A Diabetes Outcome Progression Trial
Thiazide diuretics, Potassium, and the Development of Diabetes A Quantitative Review Hypertension2006_219.
Adding Prandial Insulin to Basal Insulin: Key Challenges
Tresiba- insulin degludec
Insulin degludec (Tresiba®)
Biphasic insulin aspart 30 + metformin vs once-daily insulin glargine + glimepiride Kann P, Regulski M, Medding J, Ligthelm R A study in people with type.
Copyright © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 18 Systematic Review and Meta-Analysis.
An initiative of South Asian Federation of Endocrine Societies (SAFES)
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年5月1日 8:20-8:50 B 棟8階 カンファレンス室.
Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomized open-label controlled trial Yves.
1 INTRODUCTION Nearly 25% of diabetes patients use insulin Many practitioners: –Are uncomfortable with insulin dosing –Base dosing decisions on empiric.
Gerti Tashko, M.D. DM Journal Club 12/16/2010. The use of exenatide with insulin is not FDA approved. The study was designed to evaluate if exenatide.
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
 Insulin Degludec  Ultra long action  Due to formation of soluble multihexamers at the injection site from which monomers gradually separate and are.
R2. Sun Hee Park/Prof. Moon Chan Choi
Glycemia Treatment Strategies Used In ACCORD
Key publication slides
Sample Journal Club Your Name Here.
Mastery of Medicine in Diabetes Management Video Roundtable
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
Key publication slides
Neal B, et al. Diabetes Care 2015;38:403–411
Supplementary Table 1. PRISMA checklist
Insulin Detemir versus Glyburide in Women with
Cycloset®A Dopamine Receptor Agonist Cycloset® -Bromocriptine: Safety Trial: Post Hoc Analysis of Cumulative Percent MACE Endpoint Bromocriptine (Parlodel)
Foroutan N1,2, Muratov S1,2, Levine M1,2
Osborne K.B., Davies S.J., Coppini D.V.
MK-0431 P051 PDT APPROVED 4/10/09 11/13/2018 2:49 PM
The Next Generation of Basal Insulins
↑- likely due to hypoglycemia and weight gain
Diabetes Journal Club Julie Shah.
Examining CV Effects of Basal Insulin Therapy
Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.
Vicious Circle(s) of Hyperinsulinemia- Result in Weight Gain and Hypoglycemia Undue Or bolus Hypoglycemia Symptomatic or not!
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Treatment Pathway for Adults with Type 1 Diabetes
Key Insulin Side Effects*
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
Are All Novel Insulins Proven to Be Equally Safe?
Does cinnamon reduce fasting blood glucose in Type II diabetics?
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
Insulin Delivery Systems Atlanta Diabetes Associates
Presentation transcript:

In the name of GOD In the name of GOD

Long-acting insulin analogues versus NPH human insulin in type 2 diabetes A meta-analysis Sara Sadri

case scenario A 50 years old woman who is known case of diabet type 2 with uncontrolled diabet despite use of metformin TDS, now we want to start basal insulin for her. Which type of insulin is the best choice for treatment the patient ?

PICO PATIENT OR PROBLEM A 50 years old woman known case of diabet type 2 that diabet not controlled with metformin INTERVENTION Start Insulin Glargin COMPERTION Insulin NPH Out comes Witch of insulin is the best choice for this patient

Insulin Glargine Insulin NPH

Introduction Basal insulin can be provided using either NPH human insulin or long-acting insulin analogues. Analogues, which are more expensive than NPH insulin, should warrant a greater reproducibility of absorption after subcutaneous injection, providing better metabolic control with reduced hypoglycemic risk . .

A recent meta-analysis of eight randomized clinical trials failed to detect any difference in HbA1c, while confirming an advantage with regard to incidence of hypoglycemia.Some further trial has been published in the last few months, potentially adding relevant information .

The two currently available insulin analogues, glargine and detemir, could have different effects on body weight the aims of the present meta-analysis is the assessment of differences with respect to weight gain between NPH human insulin and each long-acting analogue. This parameter had not been considered in the meta-analysis cited above

. Research design and methods A meta-analysis was performed including all randomized clinical trials, either with a cross-over or a parallel series design, enrolling patients with type 2 diabetes, with a duration of at least 12 weeks, comparing a long-acting insulin analogue (detemir or glargine) and human NPH insulin, either combined with oral hypoglycemic agents or with a prandial insulin comparable in all treatment arms.

Trials with a shorter duration were excluded, due to the fact that they could not yield relevant information on glycated hemoglobin, which had been chosen as the principal outcome variable. An extensive Medline search for ‘‘detemir’’ and ‘‘glargine’’ was performed, collecting all randomized clinical trials on humans up to 10th February 2008.

The principal outcome was the effect of long-acting analogues, compared with NPH human insulin, on HbA1c at the end of the trial. Secondary outcomes included body mass index (BMI) at the end of the trial. Furthermore, data on the incidence of symptomatic, nocturnal, severe, or any hypoglycemia(number of patients with at least one event) were extracted. Whenever possible, separate analyses were performed for trials with different insulin analogues (detemir and glargine).

. Results The trial flow is summarized in Fig. 1, and the characteristics of the trials included in the meta-analysis are summarized in Table 1, while outcomes are reported in Table 2 Of the 14 retrieved trials, which were all open-label, three reported a significant improvement of HbA1c with analogues ,while in the remaining 11 studies no difference was detected between groups with respect to HbA1c.

Overall , long-acting analogues did not produce any significant improvement of HbA1c, in comparison with NPH human insulin. When trials with different analogues were analysed separately, NPH showed a significant superiority (by 0.1%) over detemir, but not over glargine

Two out of three trials with detemir , and one out of 11 trials with glargine , reported a significantly smaller weight gain in comparison with NPH insulin. BMI at the end of the trial was reported in 11 trials; combining the results of those studies, detemir, but not glargine, was associated with a significantly smaller weight gain than human insulin .

The total number of patients reporting at least one episode of hypoglycemia was reported only in six studies ;meta-analysing those results, long-acting analogues were associated with a significant reduction of hypoglycemic risk in comparison with NPH insulin .

The incidence of severe hypoglycemia was reported by all trials except 5,with a total number of patients experiencing at least one episode of 32 and 36 in the analogue and NPH group, respectively; the difference between treatment arms did not reach statistical significance . Symptomatic hypoglycemic episodes were reported in seven trials .

while the incidence of nocturnal hypoglycemia was described for all trials except 4 . For both these parameters, long-acting analogues showed a significant advantage over NPH insulin .

. Discussion Long-acting insulin analogues have been suggested as an alternative to NPH insulin in the treatment of both type 1 and type 2 diabetes . The higher cost of these drugs should be justified by a greater reproducibility of absorption, leading to better glycemic control and reduced risk of hypoglycemia.

Although some trials showed a reduction in HbA1c with long-acting analogues in comparison with NPH , no such difference was detected when combining the results of all available studies. This result confirms a previous metaanalysis performed on a smaller number of trials .

It should be considered that many of the recent trials on basal insulin in type 2 diabetes are performed following the so-called ‘‘treat to- target’’ scheme, which provides algorithms based on fasting glucose for an adjustment of insulin doses; this somewhat aggressive approach may reduce potential differencesin efficacy between treatments.

Once the desired glycemic target has been reached, the drug to be preferred should be the one associated with the lowest hypoglycemic risk. The present meta-analysis confirms that long-acting analogues are associated with a significant reduction in the rate of overall, nocturnal and symptomatic hypoglycemia, as previously reported in patients with type 2 and type 1 diabetes. No difference was detected for severe hypoglycemia,but this could be due to the relatively small number of events.

Detemir, unlike glargine, appears to determine a smaller weight gain in comparison with NPH insulin, as previously suggested by the results of two trials . This observation is consistent with the results of a direct comparison between the two long-acting insulin analogues, showing a similar efficacy on HbA1c, with smaller weight gain for detemir . The difference in BMI between detemir and NPH insulin is relatively small;

Some limitation of this meta-analysis should be recognized. Most of the trials were sponsored by manufacturers of long-acting analogues. Furthermore, the description of trials in available papers was often inadequate.

Differences in the criteria used for the definition of hypoglycemia should also be considered when interpreting results on the rates of nocturnal, symptomatic, or any hypoglycemia; the only consistent definition of hypoglycemia across trials is that of severe hypoglycemia, i.e. low blood glucose requiring help from a third party.

In conclusion, the use of long-acting insulin analogues in type 2 diabetic patients does not seem to provide a better glycemic control in comparison with NPH insulin, whereas it reduces the risk of nocturnal and symptomatic hypoglycemia. Detemir, but not glargine, could be associated with smaller weight gain than NPH insulin. Further studies are needed to assess possible differences among long-acting analogues.

– Differences (with 95%CI) between long-acting analogues and NPH insulin in the incidence of any, severe, symptomatic, and nocturnal hypoglycaemia.

– Differences (with 95%CI) between long-acting analogues and NPH insulin in the effects on HbA1c at endpoint.

– Differences (with 95%CI) between long-acting analogues and NPH insulin in the effects on BMI at endpoint.

Thanks a lot Thanks a lot